Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes

References

• Centers for Disease Control and PreventionNational Diabetes Fact Sheet, 2007Accessed February 18, 2009 Available from: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2007.pdf
   Google Scholar
• ReynoldsJKNeumillerJJCampbellRKJanumet: a combination product suitable for use in patients with Type 2 diabetesExpert Opin Investig Drugs20081715591565
   PubMed Web of Science ®Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus The Diabetes Control and Complications Trial Research GroupN Engl J Med19933299779868366922
   PubMed Web of Science ®Google Scholar
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) GroupLancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• CefaluWTEvaluation of alternative strategies for optimizing glycemia: progress to dateAm J Med2002113Suppl 6A23S35S12431759
   PubMed Web of Science ®Google Scholar
• KrentzAJPatelMBBaileyCJNew drugs for type 2 diabetes mellitus: what is their place in therapy?Drugs2008682131216218840004
   PubMed Web of Science ®Google Scholar
• HolstJJGromadaJRole of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humansAm J Physiol Endocrinol Metab2004287E199E20615271645
   PubMed Web of Science ®Google Scholar
• HolstJJDeaconCFInhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetesDiabetes199847166316709792533
   PubMed Web of Science ®Google Scholar
• GallwitzBSitagliptin with metformin: profile of a combination for the treatment of type 2 diabetesDrugs Today (Barc)20074368168917987221
   PubMed Web of Science ®Google Scholar
• VerdichCFlintAGutzwillerJPA meta-analysis of the effect of glucagon-like peptide-1 (7–36) amide on ad libitum energy intake in humansJ Clin Endocrinol Metab2001864382438911549680
   PubMed Web of Science ®Google Scholar
• DeaconCFAhrenBHolstJJInhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes?Expert Opin Investig Drugs20041310911102
   PubMed Web of Science ®Google Scholar
• WettergrenASchjoldagerBMortensenPEMyhreJChristiansenJHolstJJTruncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in manDig Dis Sci1993386656738462365
   PubMed Web of Science ®Google Scholar
• NauckMANiedereichholzUEttlerRGlucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humansAm J Physiol1997273E981E9889374685
   PubMed Web of Science ®Google Scholar
• MillerSSt OngeELSitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesAnn Pharmacother2006401336134316868220
   PubMed Web of Science ®Google Scholar
• HolstJJDeaconCFGlucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitorsDiabetologia20054861261515759106
   PubMed Web of Science ®Google Scholar
• WiernspergerNFBaileyCJThe antihyperglycaemic effect of metformin: therapeutic and cellular mechanismsDrugs199958Suppl 13139 discussion, 75–8210576523
   PubMed Web of Science ®Google Scholar
• YasudaNInoueTNagakuraTEnhanced secretion of glucagon-like peptide 1 by biguanide compoundsBiochem Biophys Res Commun200229877978412419322
   PubMed Web of Science ®Google Scholar
• MannucciEOgnibeneACremascoFEffect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjectsDiabetes Care20012448949411289473
   PubMed Web of Science ®Google Scholar
• ScottRWuMSanchezMSteinPEfficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetesInt J Clin Pract20076117118017156104
   PubMed Web of Science ®Google Scholar
• NonakaKKakikawaTSatoAEfficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetesDiabetes Res Clin Pract20087929129817933414
   PubMed Web of Science ®Google Scholar
• AschnerPKipnesMSLuncefordJKSanchezMMickelCWilliams-HermanDEEffect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care2006292632263717130196
   PubMed Web of Science ®Google Scholar
• RazIHanefeldMXuLCariaCWilliams-HermanDKhatamiHEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia2006492564257117001471
   PubMed Web of Science ®Google Scholar
• HanefeldMHermanGAWuMMickelCSanchezMSteinPPOnce-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurr Med Res Opin2007231329133917559733
   PubMed Web of Science ®Google Scholar
• NauckMAMeiningerGShengDTerranellaLSteinPPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trialDiabetes Obes Metab2007919420517300595
   PubMed Web of Science ®Google Scholar
• CharbonnelBKarasikALiuJWuMMeiningerGEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care2006292638264317130197
   PubMed Web of Science ®Google Scholar
• BrazgRXuLDalla ManCCobelliCThomasKSteinPPEffect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetesDiabetes Obes Metab2007918619317300594
   PubMed Web of Science ®Google Scholar
• HermansenKKipnesMLuoEFanurikDKhatamiHSteinPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab2007973374517593236
   PubMed Web of Science ®Google Scholar
• GoldsteinBJFeinglosMNLuncefordJKJohnsonJWilliams-HermanDEEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care2007301979198717485570
   PubMed Web of Science ®Google Scholar
• ScottRLoeysTDaviesMJEngelSSEfficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetesDiabetes Obes Metab20081095996918201203
   PubMed Web of Science ®Google Scholar
• LangleyAKSuffolettaTJJenningsHRDipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitusPharmacotherapy2007271163118017655515
   PubMed Web of Science ®Google Scholar
• StevensCBergmanALiuQLack of clinically significant effect of moderate hepatic insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a dipeptidyl-peptidase-IV inhibitor [abstract no. PII-49]Clin Pharmacol Ther200679116413236
   PubMed Web of Science ®Google Scholar
• BergmanAJCoteJYiBEffect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitorDiabetes Care2007301862186417468348
   PubMed Web of Science ®Google Scholar
• ScheenAJClinical pharmacokinetics of metforminClin Pharmacokinet1996303593718743335
   PubMed Web of Science ®Google Scholar
• AmoriRELauJPittasAGEfficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysisJAMA200729819420617622601
   PubMed Web of Science ®Google Scholar
• RichterBBandeira-EchtlerEBergerhoffKLerchCLDipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitusCochrane Database Syst Rev20082CD00673918425967
   PubMedGoogle Scholar
• RosenstockJBrazgRAndryukPJLuKSteinPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther2006281556156817157112
   PubMed Web of Science ®Google Scholar
• BergmanAJCoteJMaesAEffect of sitagliptin on the pharmacokinetics of simvastatinJ Clin Pharmacol20094948348819204138
   PubMed Web of Science ®Google Scholar
• MistryGCBergmanAJLuoWLMultiple-dose administration of sitagliptin, a dipeptidyl peptidase-4 inhibitor, does not alter the single-dose pharmacokinetics of rosiglitazone in healthy subjectsJ Clin Pharmacol20074715916417244766
   PubMed Web of Science ®Google Scholar
• KrishnaRBergmanALarsonPEffect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjectsJ Clin Pharmacol20074716517417244767
   PubMed Web of Science ®Google Scholar
• MillerJLMigoyaETJEThe effect of MK-0431 on the pharmakokinetics of digoxin after concomitant administration for 10 days in healthy subjectsClin Pharmacol Ther200679
   Web of Science ®Google Scholar
• Janumet^TM (sitagliptin/metformin HCl) Tablets [package insert]Whitehouse Station, NJMerck Pharmaceuticals, Inc2007
   Google Scholar
• MelikianCWhiteTJVanderplasADeziiCMChangEAdherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapyClin Ther20022446046711952029
   PubMed Web of Science ®Google Scholar
• BlondeLWogenJKreilickCSeymourAAGreater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metforminDiabetes Obes Metab2003542443114617228
   PubMed Web of Science ®Google Scholar
• VanderpoelDRHusseinMAWatson-HeidariTPerryAAdherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysisClin Ther2004262066207515823770
   PubMed Web of Science ®Google Scholar
• SarafidisPAThiazolidinedione derivatives in diabetes and cardiovascular disease: an updateFundam Clin Pharmacol20082224726418422634
   PubMed Web of Science ®Google Scholar